Table 10.14Exenatide + glitazone vs placebo + glitazone

Zinman167 N=233 T=16 weeksGlitazone + placeboGlitazone + exenatideSize effect
HbA1c+0.09%−0.89%−0.98% (95% CI −1.21 to −0.74%, p<0.01)
Fasting serum glucose+0.10 mmol/l−1.59 mmol/l−1.69 mmol/l (95% CI −2.22 to −1.17 mmol/l, p<0.001)
Body weight−0.24 kg−1.75 kg−1.51 kg CI −2.15 to −0.88 kg, p<0.001)
Lipid profileThe study reported that no clinically significant changes occurred
AEsThe most frequent AE was nausea, which was the reason for withdrawal of 9% and 1% of patients in the exenatide and placebo groups respectively
The incidence of treatment-emergent oedema was similar in both groups (5.8% and 8% of patients in the exenatide and placebo groups respectively)
The overall incidence of hypoglycaemia was also low and similar between groups (10.7% and 7.1% of patients in the exenatide and placebo groups respectively)

From: 10, Oral glucose control therapies (2): other oral agents and exenatide

Cover of Type 2 Diabetes
Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update).
NICE Clinical Guidelines, No. 66.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2008, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.